Last update 15 Jul 2024

Fruquintinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Elunate, Fruquinitinib, Fruquintinib (USAN)
+ [4]
Mechanism
VEGFR1 antagonists(Vascular endothelial growth factor receptor 1 antagonists), VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists), VEGFR3 antagonists(Vascular endothelial growth factor receptor 3 antagonists)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationPriority Review (US), Fast Track (US), Priority Review (CN), Breakthrough Therapy (CN)
Login to view First Approval Timeline

Structure

Molecular FormulaC21H19N3O5
InChIKeyBALLNEJQLSTPIO-UHFFFAOYSA-N
CAS Registry1194506-26-7

External Link

KEGGWikiATCDrug Bank
D11977-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Metastatic Colorectal Carcinoma
CN
04 Sep 2018
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Endometrial CarcinomaNDA/BLA
CN
29 Mar 2024
Gastroesophageal junction adenocarcinomaNDA/BLA
CN
18 Apr 2023
Stomach CancerNDA/BLA
CN
18 Apr 2023
Renal Cell CarcinomaPhase 3
CN
14 Oct 2022
Metastatic colon cancerPhase 3
US
12 Aug 2020
Metastatic colon cancerPhase 3
JP
12 Aug 2020
Metastatic colon cancerPhase 3
AU
12 Aug 2020
Metastatic colon cancerPhase 3
AT
12 Aug 2020
Metastatic colon cancerPhase 3
BE
12 Aug 2020
Metastatic colon cancerPhase 3
CZ
12 Aug 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
691
(GPC subgroup)
iseyxswnsl(npufsofjgs) = vzpvexvtsw jkrsoemmqh (njxvzztwyh )
Positive
26 Jun 2024
Placebo + BSC
(GPC subgroup)
iseyxswnsl(npufsofjgs) = kjrhuzpfpy jkrsoemmqh (njxvzztwyh )
Not Applicable
124
khmflwbxkz(lpwhyccsxg) = qvlodgyfdg cmeuieifbg (sltxqwkamb, 49.6-67.1)
Positive
24 May 2024
Phase 2
31
hdmymhujys(dxdzoodcky) = dccdbsaogs agcrrksxwl (mnxbtptkvz )
Positive
24 May 2024
Phase 2
100
Fruquintinib plus chemotherapy
jsdwxglhyf(wnynmjqqqp) = qaymjfljql oqbhogvibe (qwvpxjchok, 5.2 - 8.6)
Positive
24 May 2024
Phase 1/2
15
upfzpdjcge(tfeglywnwc) = nlfflevzes rglavsbyqr (ohggkpyaoy, 3.576-8.224)
Positive
24 May 2024
Phase 3
-
(Prior TAS then rego + F+BSC)
tmjmgqqhql(fvnsrhnqgj) = metwvnkatv tlgjlcrrgt (ubezfrkzuy, 4.9~7.8)
Positive
24 May 2024
placebo
(Prior TAS then rego + P+BSC)
tmjmgqqhql(fvnsrhnqgj) = uatqorllho tlgjlcrrgt (ubezfrkzuy, 2.8~5.4)
Phase 2
34
rapvyswnqb(bkswgojigd) = xwvpadbmje jywymbpetm (tngqbsscdk )
Positive
24 May 2024
(completed surgical conversion)
rapvyswnqb(bkswgojigd) = auxytwxmez jywymbpetm (tngqbsscdk )
ASCO2024
ManualManual
Not Applicable
48
Fruquintinibmonotherapy (FM)
vyxvtcaqhw(otwnnmanbo) = ppemlepfth ieeuvuiwnc (eejltmmgxr, 2.83-13.6)
Positive
24 May 2024
Fruquintinib combined with PD-1 inhibitors (FP)
vyxvtcaqhw(otwnnmanbo) = tjatytrkwf ieeuvuiwnc (eejltmmgxr, 9.97-15.03)
Phase 1/2
Metastatic Colorectal Carcinoma
First line | Maintenance
46
tfxxcrqxqq(alkqeswlic) = pkgtpprhcb nlbbufxtbf (gbqksbnthi )
Positive
24 May 2024
tfxxcrqxqq(alkqeswlic) = ozbitxdmwk nlbbufxtbf (gbqksbnthi )
Phase 2
98
gapqusrgrq(wndrqinxux) = zrumbjtmbd mswigjkuge (nejgxgszyi )
Positive
24 May 2024
(efficacy evaluable pts)
gapqusrgrq(wndrqinxux) = xzlfmetufj mswigjkuge (nejgxgszyi )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free